Introduction: Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung Cancer Master Protocol Southwest Oncology Group S1400 enrolled patients with previously treated stage IV or recurrent SqCC to assess NGS biomarkers for therapeutic sub-studies., Methods: Tumors underwent NGS using Foundation Medicine's FoundationOne research platform, which sequenced the exons and/or introns of 313 cancer-related genes. Mutually exclusive gene set analysis and Selected Events Linked by Evolutionary Conditions across Human Tumors were performed to identify mutually exclusive and co-occurring gene alterations. Comparisons were performed with data on 495 lung SqCC downloaded from The Cancer Genome Atlas. Cox proportional hazards models were used to assess associations between genetic variants and survival., Results: NGS data are reported for 1672 patients enrolled on S1400 between 2014 and 2019. Mutually exclusive gene set analysis identified two non-overlapping sets of mutually exclusive alterations with a false discovery rate of less than 15%: NFE2L2, KEAP1, and PARP4; and CDKN2A and RB1. PARP4, a relatively uncharacterized gene, showed three frequent mutations suggesting functional significance: 3116T>C (I1039T), 3176A>G (Q1059R), and 3509C>T (T1170I). When taken together, NFE2L2 and KEAP1 alterations were associated with poorer survival., Conclusions: As the largest dataset to date of lung SqCC profiled on a clinical trial, the S1400 NGS dataset establishes a rich resource for biomarker discovery. Mutual exclusivity of PARP4 and NFE2L2 or KEAP1 alterations suggests that PARP4 may have an uncharacterized role in a key pathway known to impact oxidative stress response and treatment resistance., Competing Interests: Disclosure Dr. Kozono discloses consulting for Vertex and Roche/Genentech and honoraria from RefleXion outside the submitted work. Dr. Tolba discloses employment at Foundation Medicine. Dr. Waqar discloses holding positions on scientific advisory boards for AstraZeneca and Gilead Sciences. Dr. Dragnev discloses receiving institutional research funding from Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Merck, Molecular Templates, Novartis, Roche/Genentech. Dr. Cheng discloses receiving honoraria from AstraZeneca, Janssen, G1 Therapeutics, and research grants from AstraZeneca, and Genentech. Dr. Hirsch discloses holding positions on scientific advisory boards for BMS, AstraZeneca, Daiichi Sankyo, Sanofi, Novartis, AbbVie, Novocure, NextCure, Merus, G1 Therapeutics, Regeneron, none related to this work, and holding patent for EGFR protein and gene copy number as predictive biomarkers for EGFR-directed therapies (through University of Colorado), no royalties. Dr. Mack discloses being a consultant for Amgen, Guardant Health, and Vivance Therapeutics, and receiving honoraria from AbbVie (educational lecture). Dr. Gray discloses being a consultant for AbbVie, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, EMD Serono – Merck, Gilead Sciences, IDEOlogy Health, Janssen Scientific Affairs, Jazz Pharmaceuticals, Loxo Oncology, Merck and Company, Novartis, OncoCyte Biotechnology, Spectrum ODAC, Takeda Pharmaceuticals, Triptych Health Partners; research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, G1 Therapeutics, Ludwig Institute of Cancer Research, Merck and Company, Novartis, Pfizer. Dr. Borghaei discloses receiving research support for clinical trials from BMS, Lilly, Amgen and holding positions on advisory board/consultant for BMS, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi Sankyo, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Puma, BerGenBio, Bayer, Iobiotech, Grid Therapeutics, holding position on data and safety monitoring board for University of Pennsylvania: CAR T Program, Takeda, Incyte, Novartis, Springworks, holding position on the scientific advisory board for Sonnetbio (stock options), Inspirna (formerly Rgenix, stock options), Nucleai (stock options), and receiving honoraria from Amgen, Pfizer, Daiichi Sankyo, Regeneron, travel support from Amgen, BMS, Merck, Lilly, EMD-Serono, Genentech, Regeneron, Mirati. Dr. Herbst discloses holding positions on the board of directors for Immunocore, Junshi Pharmaceuticals, being consultant for AbbVie Pharmaceuticals, AstraZeneca, Bolt Biotherapeutics, Bristol-Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Genentech, Gilead, HiberCell, I-Mab Biopharma, Immune-Onc Therapeutics, Immunocore, Janssen, Johnson and Johnson, Loxo Oncology, Merck and Company, Mirati Therapeutics, NextCure, Normunity, Novartis, Ocean Biomedical, Oncocyte Corp, Oncternal Therapeutics, Pfizer, Regeneron Pharmaceuticals, Revelar Biotherapeutics, Ribbon Therapeutics, Roche, Sanofi, Seattle Genetics, Xencor, receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company, and holding leadership roles in American Association for Cancer Research, International Association for the Study of Lung Cancer, Society for Immunotherapy of Cancer, Southwest Oncology Group. Dr. Gandara discloses being a consultant for Adagene (institutional), AstraZeneca (institutional), Guardant Health (institutional), IO Biotech (institutional), Oncocyte (institutional), Oncohost (institutional), Merck (consultant), Roche-Genentech (institutional) and receiving institutional research grants from Amgen, AstraZeneca, Genentech, Merck. The remaining authors declare no conflict of interest., (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)